2024-ASC-STUDENT
23.4.2024 09:03:33 CEST | Business Wire | Press release
On April 13, 2024, the 2024 ASC Student Supercomputer Challenge (ASC24) Finals drew to a close at Shanghai University after five days of intense competition. Peking University emerged as the undisputed overall champion, securing their place in ASC Student Supercomputer Challenge history.
After ASC24 registration opened on November 16, 2023, over 300 teams from universities participated in the intense preliminary contests. As a result, the absolute best 25 teams ascended to the finals hosted at Shanghai University from April 9 to 13, 2024. This marked a groundbreaking moment in ASC history, with the highest number of teams ever qualifying for onsite finals since the competition's inception in 2012.
During the finals, teams showcased their skills by designing and building cluster systems capped at a maximum power consumption of 3,000 W. They tackled a lineup of cutting-edge scientific and engineering applications, including HPL and HPCG benchmarks, Large Language Model (LLM), OpenCAEPoro, GoMars, and WannierTools. ASC24 featured again a group competition in which 25 teams, divided into 5 groups, explored the real-world application of ParaSeis. They simulated seismic wave propagation and refined algorithms through collaborative communication.
The competition reached its pinnacle when Peking University ultimately seized the coveted Champion title. Their performance not only impressed everyone but also demonstrated exceptional proficiency across various tasks such as GoMars, LLM, and WannierTools. This showed their expertise and unequaled mastery of comprehensive supercomputing systems, applications, and top-tier optimization skills.
The National Tsing Hua University team achieved significant results with the OpenCAEPoro task. They maximized the use of computing resources, executed large-scale parallel optimization of OpenCAEPoro while navigating power consumption constraints, and achieved the shortest run time, securing them the prestigious e Prize.
A collaborative effort led by Shanghai University, in partnership with the Southern University of Science and Technology, Qilu University of Technology, Southwest Petroleum University, and Hong Kong Polytechnic University, achieved remarkable optimization of ParaSeis. Their commendable teamwork and dedication were duly recognized with the prestigious Group Competition Award.
Additionally, the Zhejiang University team secured the Highest LINPACK Award, showcasing their exceptional computational prowess. Meanwhile, the outstanding performances of Shanxi University and Shanghai Jiao Tong University were properly honored with the coveted Application Innovation Award, recognizing their innovative contributions to the field.
Jack Dongarra, a distinguished member of the US National Academy of Engineering and recipient of the prestigious Turing Award, as well as a Distinguished Professor at both Oak Ridge National Laboratory and the University of Tennessee, and Chair of the ASC Advisory Committee, shared his insights during the closing ceremony of the ASC24 Finals: "ASC challenges and inspires the next generation of HPC scientists and engineers to deliver innovative solutions using the most cutting-edge technologies. The competition has been described as the world’s largest supercomputing hackathon, striving to foster the next generation of young talents to inspire exploration, innovation, and collaboration in Supercomputing and AI."
About ASC
The ASC Student Supercomputer Challenge stands as the globe's premier student supercomputer competition, with the generous support of experts and institutions spanning Asia, Europe, and America. ASC boasts a noble mission: to foster the exchange and cultivation of young supercomputing talent across borders, enhance supercomputing applications and research and development capabilities, propel the advancement of supercomputing technologies, and stimulate technical and industrial innovation. Since its inception in 2012, the ASC Student Supercomputer Challenge has grown every year, attracting over 10,000 undergraduates from every corner of the planet. To discover more about this impactful endeavor, visit the website.
http://www.asc-events.net/StudentChallenge/index.html
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240423424820/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
